PRAISE-IR Versus CIBMTR Controls
NCT07717164 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 51
Last updated 2026-07-28
Summary
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
Conditions
- ALL (Acute B-Lymphoblastic Leukemia)
- AML (Acute Myeloid Leukemia)
- MDS (Myelodysplastic Syndrome)
Sponsors & Collaborators
-
Miltenyi Biomedicine GmbH
lead INDUSTRY
Eligibility
- Min Age
- 1 Year
- Max Age
- 66 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-31
- Primary Completion
- 2026-09-20
- Completion
- 2026-09-30
Countries
- United States
Study Locations
More Related Trials
-
Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
NCT01844635 ·Status: UNKNOWN ·Phase: PHASE3
-
Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT
NCT04869254 ·Status: COMPLETED
-
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-
NCT00189748 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation
NCT07381114 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
NCT00088543 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078 ·Status: RECRUITING ·Phase: PHASE2
-
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders
NCT00010335 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
NCT00472225 ·Status: UNKNOWN ·Phase: PHASE2
-
HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
NCT03456817 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
NCT03755414 ·Status: COMPLETED ·Phase: PHASE1
-
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
NCT04294641 ·Status: COMPLETED ·Phase: PHASE2
-
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
NCT06199427 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
NCT01856803 ·Status: COMPLETED ·Phase: PHASE4
-
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
NCT00017550 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
NCT05214066 ·Status: UNKNOWN ·Phase: PHASE2
-
Thymoglobulin (ATG) Dose Finding Study
NCT00409695 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Treg Cell in the Treatment of GVHD
NCT06411184 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis
NCT07440654 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
NCT07349771 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Clinical Activity of Itolizumab in aGVHD
NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
NCT03887156 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
NCT03657160 ·Status: COMPLETED ·Phase: PHASE3
-
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
NCT04095858 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
NCT02806947 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
NCT05599256 ·Status: RECRUITING ·Phase: PHASE2